DOPHA aims to be at the forefront of Qatar’s pharmaceutical sector. DOPHA commenced operations in 2019 and was the first manufacturing facility in Qatar with a planned investment outlay of USD50 million.

The organization’s inspiration stems from the vision to locally manufacture world class pharmaceuticals at affordable prices. DOPHA global presence is supported by 5 manufacturing facilities spread across 3 continents delivering branded and generic formulations, and active pharmaceutical ingredients (APIs). The therapeutic segments covered by our portfolio of over 100 high-quality molecules include anti-infective, neurology, cardiology, orthopedics, diabology, gastroenterology, urology, dermatology, gynecology, respiratory, dental and nutritionals.

Driven by innovation, Neopharma lays strong emphasis on research, especially towards development of processes and products that are patent non-infringing. DOPHA currently caters to over 50 international markets including Middle East, Africa, CIS, Far East and South East Asia.